ContextLogic Inc. - LOGC STOCK NEWS

LogicBio Therapeutics (Nasdaq: LOGC) has announced that the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application (IND), allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with methylmalonic acidemia. The FDA's decision follows satisfactory resolutions of previous clinical hold issues, including two cases of thrombotic microangiopathy. The company plans to implement enhanced monitoring measures and resumes dosing by Q3 2022, with interim clinical data expected by the end of Q2 2022.

LogicBio Therapeutics (Nasdaq: LOGC) announced that CEO Frederic Chereau will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference. The presentation will be available on demand starting at 7:00 a.m. ET on March 30, 2022. A webcast of the presentation can be accessed in the Investors section of the company's website, with a replay available for approximately 30 days. LogicBio focuses on genome editing and gene delivery for rare diseases, utilizing its GeneRide™ and sAAVy™ platforms.

LogicBio Therapeutics, Inc. (Nasdaq: LOGC) announced that CEO Frederic Chereau will participate in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET. The discussion will be accessible via a live webcast on the Company's website and will remain available for approximately 30 days post-event. LogicBio focuses on innovative genetic medicine solutions, including its GeneRide™ platform for gene insertion and sAAVy™ for optimized gene delivery, aimed at treating rare diseases across all age groups. For further details, visit their website.

LogicBio Therapeutics (Nasdaq: LOGC) reported financial results for the year ending December 31, 2021, showcasing a revenue increase to $5.4 million from $3.5 million in 2020, driven by collaboration revenues. R&D expenses rose to $28.2 million, while G&A expenses climbed to $16.2 million, contributing to a net loss of $40.0 million, or $1.24 per share. The company experienced a clinical hold on LB-001 after a serious adverse event, though it resolved. LogicBio maintains a cash position of $53.5 million, projected to fund operations through Q1 2023.

LogicBio Therapeutics (LOGC) announced that the FDA has placed a clinical hold on its Phase 1/2 SUNRISE trial of LB-001, a gene therapy for methylmalonic acidemia (MMA), due to safety concerns following serious adverse events in two pediatric patients. Despite successful dosing of four patients, including two who reported no drug-related issues, the trial's future is uncertain as LogicBio collaborates with the FDA for next steps. The company has suspended guidance on interim data until further clarity is achieved.

LogicBio Therapeutics (Nasdaq:LOGC) announced that CEO Fred Chereau will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference from January 10-13, 2022. The pre-recorded presentation will be available for on-demand viewing starting January 10, 2022, at 7:00 a.m. ET. A webcast of the presentation can be accessed on the company's investors page and will be available for 30 days.

LogicBio specializes in genetic medicine, focusing on genome editing and gene delivery technologies for rare diseases.

LogicBio Therapeutics, a clinical-stage genetic medicine company, updated stakeholders on its SUNRISE Phase 1/2 clinical trial, demonstrating in vivo genome editing in pediatric patients with methylmalonic acidemia. Although a serious adverse event occurred during the trial, the company reported the patient has recovered. LogicBio also nominated a new development candidate, LB-401, for hereditary tyrosinemia type 1, showing promising preclinical results. Additionally, Susan R. Kahn was appointed to the Board of Directors, bringing a wealth of experience in rare disease advocacy.

LogicBio Therapeutics (Nasdaq: LOGC) reported their third quarter financial results for 2021, showing a revenue increase to $2.1 million, up from $0.9 million in Q3 2020. R&D expenses rose to $7.8 million, while G&A expenses increased to $4.3 million, leading to a net loss of $10.2 million or $0.31 per share. The company anticipates announcing interim data from its Phase 1/2 SUNRISE trial for LB-001 in pediatric patients with methylmalonic acidemia by year-end. LogicBio holds $59.6 million in cash, funding operations into Q4 2022.

LogicBio Therapeutics (Nasdaq:LOGC) announced its president and CEO, Frederic Chereau, will participate in two upcoming investor conferences. The Barclays Gene Editing & Gene Therapy Summit features a fireside chat on November 15, 2021, at 8:00 a.m. ET. The Jefferies Virtual London Healthcare Conference will have a pre-recorded presentation available starting at 3:00 a.m. ET on November 18, 2021. Both events will be accessible via the Company’s website for 30 days. LogicBio focuses on genetic medicine targeting rare diseases with innovative gene editing and delivery technologies.